FDA Inspection 1144990 — Huatai Biopharm Inc.
The FDA completed an inspection of Huatai Biopharm Inc. on May 23, 2019 in Deyang. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action). Product area: Drugs.
Inspection Details
- Classification
- Voluntary Action Indicated (VAI)
- End Date
- May 23, 2019
- Fiscal Year
- 2019
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Deyang (China)
Additional Details
Mutual Recognition Agreement (MRA)